Preclinical models evaluating the combination of OKI-179 and the MEK inhibitor binimetinib in RAS-pathway cancers found that the combination is synergistic and results in increased DNA damage, leading to apoptosis [33]. This evidence concerns the gene MAP2K7 and cancer.